CompletedPhase 4

Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion

Austria, Denmark130 participantsStarted 2012-12

Plain-language summary

Patients with need of platelet transfusion for any reason will participate in this study. Directly before the start of infusion and one hour after the end of platelet transfusion blood samples will be drawn and treated with different concentrations of Fibrinogen (a blood clotting factor) in-vitro. Blood samples with and without Fibrinogen/platelet transfusion will be compared. The study hypothesis is that treatment with Fibrinogen results in a better stabilisation of blood coagulation.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patient with the clinical need for platelet transfusion * age: 18 - 85 years Exclusion Criteria: * pregnant or nursing women * patients who disagree to participate in the study * for emergency patients: patients with known refusal of a participation in this clinical trial * active participation in a clinical trial * any condition, including the presence of laboratory abnormalities, which would place confound in the ability to interpret data from the study * any serious medical condition, laboratory abnormalities, or psychiatric illness, that would prevent the subject from signing the informed consent form

What they're measuring

difference in A30 (ExTEM®) between blood samples after in vitro spiking and compared to those blood samples obtained from the same patients after platelet transfusion

Timeframe: 1 hour after platelet transfusion

Trial details

NCT IDNCT01955811

SponsorMedical University Innsbruck

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-08

View on ClinicalTrials.gov More Blood Platelet Transfusion trials